Introduction {#S1}
============

The kidney develops as a result of interactions between the the ureteric bud (UB) and the metanephric mesenchyme (MM)^[@R1]^. The UB invades the MM and undergoes a series of branchings forming the collecting duct system and ureter of the mature kidney^[@R1]^. The UB also induces a condensation and epithelialization of the MM to form comma and S-shaped bodies. The mechanisms responsible for UB branching and MM condensation have been thoroughly studied over the years with important progress being made^[@R1]^. By contrast, the mechanisms responsible for the subsequent steps of maturation have been the focus of more recent studies, and many outstanding questions remain^[@R1]^. Comma and s-shaped bodies are composed of an immature epithelium with a central lumen, which will undergo a program of patterning. Both MM- and UB-derived structures undergo a program of tubular elongation necessary to generate the mature nephron and collecting duct system, respectively^[@R2]^.

Recent important progress has been made in understanding the mechanisms underlying the elongation process as well as the establishment and maintenance of tubular diameter^[@R1],[@R2],[@R3]^. This process is achieved by at least two mechanisms. During embryonic development both the collecting duct and the proximal tubules decrease in diameter. While cell division is randomly oriented at these stages, tubular elongation involves a process similar to convergent extension (CE) movements, which are known to cause narrowing and elongation of tissues in several systems^[@R1]^. It was recently shown that epithelial cells composing the tubules achieve a precise orientation and elongate mediolaterally, in a process resulting in cellular intercalation^[@R3],[@R4]^. This process depends on the planar cell polarity pathway (PCP) and involves the formation and resolution of rosettes, in a process closely resemblying CE^[@R3]^. Once this initial phase of morphogenesis is completed (approximately at postnatal day 1 in most collecting ducts in the mouse) and the optimal tubular diameter is reached, further elongation of the tubule is achieved by oriented (proximal-distal) cell division (OCD)^[@R5],[@R4]^, ensuring elongation, while preserving a correct diameter. Defects in PCP altering one or both of these processes have been proposed to contribute to cystogenesis^[@R4],[@R5],^.

Defective regulation of tubular diameter is associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD), one of the most common inherited disorders^[@R6]^. The hallmark of this disease is bilateral renal cyst formation, due to loss-of-function mutations in two genes: *PKD1* in 85% of cases or *PKD2* in the remaining 15%. Expression of the *PKD1* gene is developmentally regulated in kidneys^[@R7]^, suggesting its possible involvement in normal tubular morphogenesis. *PKD1* encodes for Polycystin-1 (PC-1), a large plasma membrane receptor of unknown function, with a very large extracellular N-terminus containing protein-protein interaction domains, 11 transmembrane domains and a short intracellular C-terminus^[@R7]^. PC-1 has been implicated in anumber of biological processes^[@R7]^, but to date its precise function remains to be defined. The role of the *Pkd1* gene in mediating OCD in the tubules of newborn kidneys has been recently investigated and lead to controversial results^[@R8],[@R9]^, while the role of PC-1 in tubular morphogenesis and CE during development was not investigated.

Here, we show that PC-1 is essential for proper establishment of tubular diameter and mediolateral cell orientation during embryonic renal development in the mouse. PC-1 directly associates with Par3 and favors the association of a Par3/aPKC complex in a process likely important for oriented cell migration and for renal tubular morphogenesis in the developing kidney. In line with this we also find that inactivation of the *Pard3* gene in the developing kidneys leads to defective CE and to a non fully-penetrant renal cystic phenotype.

Results {#S2}
=======

Defective Convergent Extension in *Pkd1^ΔC/ΔC^* Kidneys {#S3}
-------------------------------------------------------

To test if PC-1 is involved in CE during renal development, we analyzed a *Pkd1* mutant allele previously described by our group which lacks the last two exons of the gene, resulting in a mutant protein lacking the intracellular C-tail (*Pkd1^ΔC/ΔC^*)^[@R10]^. These mice die between E.16.5 and E17.5 and display renal cyst formation starting at E15.5, similar to other PKD mice models. The number of cells per cross-section of DBA-positive renal tubules in wild-type kidneys decreased over time from E13.5 to E16.5 ([Fig. 1a,b](#F1){ref-type="fig"}), indicating that their diameter decreses ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). Analysis of *Pkd1^ΔC/ΔC^* mutants showed no significant difference from wild-type at E13.5 ([Fig. 1a,b](#F1){ref-type="fig"}), but a significant defect in tubular narrowing as compared to the wild-type tubules at later stages (E15.5 and E16.5, [Fig. 1a,b,c](#F1){ref-type="fig"} and [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). Staining with Ki67, TUNEL and cleaved caspase-3, revealed that neither differences in proliferation nor in apoptosis could account for the differences between *Pkd1^+/+^* and *Pkd1^ΔC/ΔC^* tubules ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). Conversely, analysis of the morphology of epithelial cells in DBA-positive tubules revealed that the mediolateral orientation normally observed in wild-types was lost in *Pkd1^ΔC/ΔC^* developing kidneys at E15.5 ([Fig. 1d,e](#F1){ref-type="fig"} and [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}).

PC-1 Regulates Front-Rear Polarity and oriented Migration {#S4}
---------------------------------------------------------

We next aimed at investigating the molecular mechanism underlying this defect. Unfortunately, an appropriate functional assay to study CE or planar polarity *in vitro* is not available. However, the process of CE is intimately linked to the capability of cells to migrate and orient correctly. Therefore, we used cells derived from *Pkd1*^+/+^ or *Pkd1*^−/−^ mice (mouse embryonic fibroblasts, MEFs), in which we have previously reported a defect in migration rates^[@R11]^. During our assays, we noticed that in wound-healing assays *Pkd1*^−/−^ MEFs took a contorted path to fill the wound, while wild-type cells migrated in a more linear manner ([Fig. 2a, b](#F2){ref-type="fig"}). Furthermore, *Pkd1*^−/−^ cells failed to relocate their MTOC ([M]{.ul}icro[t]{.ul}ubule [o]{.ul}rganizing [c]{.ul}enter) and Golgi in front of their nuclei to generate front-rear polarity as observed in wild-type cells^[@R12],[@R13]^ ([Figure 2c](#F2){ref-type="fig"}).

Next, we isolated MEFs derived from a mouse model expressing a floxable HA-tagged endogenous PC-1 (*Pkd1^HA/HA^* or *Pkd1^flox/flox^* interchangeably)^[@R10]^. As previously described, HA-tags were inserted in-frame into the last exon of the *Pkd1* gene, resulting in expression of HA-tagged endogenous PC-1^[@R10]^. These lines also carry loxP sites flanking exon 45 and exon 46^[@R10]^. Therefore upon treatment with a Cre recombinase *Pkd1^HA/HA^* generate the *Pkd1^ΔC/ΔC^* alleles described above, that have lost the protein's C-terminus and its detectability ([Fig. 2c,f](#F2){ref-type="fig"}). Importantly, we found that these cells have lost their capability to polarize in wound-healing assays ([Fig. 2c](#F2){ref-type="fig"}).

Furthermore, a set of MDCK-typeII cells over-expressing PC-1^[@R14]^ acquired a polarized migratory phenotype as compared to controls ([Fig. 2c](#F2){ref-type="fig"}). Finally, transient over-expression of wild-type FL-PC-1, but not of the patient-derived mutant R4227X^[@R15]^ or the CTF^[@R16]^, induced front-rear polarity ([Fig. 2g and h](#F2){ref-type="fig"}). Thus, in addition to the previously described capability of PC-1 to regulate cell motility^[@R11]^, here we show that PC-1 also regulates front-rear cell polarity during migration and both the C- and the N-terminal domains are required for this activity.

PC-1 Binds the Par3/aPKC complex {#S5}
--------------------------------

While the capability of cells to reach appropriate front-rear polarity cannot be considered as an *in vitro* assay for CE, the two processes share some molecular players and mechanisms. One of these is the complex composed of aPKC and the polarity proteins Par3 and Par6, which is very important both for front-rear polarity in mammalian cells and for CE in flies and lower vertebrates^[@R17],[@R18],[@R13],[@R19],[@R20]^. Therefore, we investigated whether PC-1 could interact or regulate components of the Pars/aPKC complex. To this end, we used MEFs isolated from *Pkd1*^HA/HA^ knock-in mice ([Fig. 2f](#F2){ref-type="fig"})^[@R10]^. Immunoprecipitation studies revealed that PC-1 coprecipitates with aPKC, a fraction of which reveal phosphorylation in Thr410 ([Fig. 3a](#F3){ref-type="fig"}). In line with this, a kinase-dead mutant of aPKC abrogates front-rear polarity in MDCK*^PKD1Zeo^* cells, suggesting that this kinase is important ([Fig. 3b](#F3){ref-type="fig"}) and in line with published studies the same mutant abrogated front-rear polarity in wild-type MEFs ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}). Notably, endogenous PC-1 co-precipitated Par3, but not Par6 in *Pkd1*^HA/HA^ MEFs ([Fig. 3a](#F3){ref-type="fig"}) and in reverse immunoprecipitation studies Par3 co-precipitated PC-1 in *Pkd1*^HA/HA^ MEFs ([Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}). To define the domains involved in the interaction, we over-expressed the full-length HA-tagged PC-1 with the 180kDa or the 100kDa form of Par3, lacking the aPKC binding domain ([Fig. 3c](#F3){ref-type="fig"}) and found that the over-expressed PC-1 ([Fig. 3d](#F3){ref-type="fig"}) co-precipitated both isoforms. Furthermore, when the same two constructs were transfected into *Pkd1^HA/HA^* MEF lines, we found that endogenous PC-1 also can interact with both isoforms ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}). Next, we expressed in bacteria the three PDZ domains of Par3 each fused to GST and used them in GST pull-down assays along with a histidine-tagged intracellular C-terminal tail of PC-1 (HIS-PC-1-CT)^[@R21]^. We found that HIS-PC-1-CT binds to the first two PDZ domains of Par3, but not to the third one ([Fig. 3e](#F3){ref-type="fig"}). We conclude that PC-1 C-tail associates directly with Par3 through its first two PDZ domains. These results along with the capability of PC-1 to interact with Par3 lacking the aPKC binding domain suggest that likely Par3 mediates the interaction with aPKC.

PC-1 regulates a balance between Par3/aPKC and Par6/aPKC {#S6}
--------------------------------------------------------

Next, we looked at the distribution of Par3 in *Pkd1*^−/−^ MEFs subject to wound-healing and found that these cells fail to properly localize Par3 in distinct patches aligned along the cell-cell contacts, as in wild-type cells and as previously reported^[@R13]^ ([Fig. 4a](#F4){ref-type="fig"}). Furthermore, immunoprecipitation of aPKC from *Pkd1*^+/+^ and *Pkd1*^−/−^ cells revealed that its association with Par3 is reduced , while its association with Par6 is enhanced ([Fig. 4b,c](#F4){ref-type="fig"}). We hypothesized that changes in the ratio of the Par3 or Par6 bound to aPKC might influence polarized migration. Indeed over-expression of Par6A was able to displace Par3 from aPKC ([Supplementary Fig. S3](#SD1){ref-type="supplementary-material"}) and caused an impairment of front-rear polarity ([Fig. 4d](#F4){ref-type="fig"}). Overexpression of Par3 did not have an effect on polarity ([Fig. 4d](#F4){ref-type="fig"}), whereas its silencing impaired front-rear polarity ([Fig. 4d](#F4){ref-type="fig"} and [Supplementary Fig. S3](#SD1){ref-type="supplementary-material"}). Importantly, over-expression of wild-type Par6A in *Pkd1^HA/HA^* fibroblasts competes away the association between PC-1 and aPKC in a dose-dependent manner ([Fig. 4e](#F4){ref-type="fig"}). Using a Par6 mutant (Par6^K19A^) which lacks the capability to bind aPKC^[@R22]^, we found that the interaction between Par6 and aPKC is required for its competing activity ([Figure 4f](#F4){ref-type="fig"}) suggesting that Par6 subtracts aPKC from PC-1/Par3 by binding directly to aPKC. Thus, PC-1 associates with a Par3/aPKC complex (which is in competition with a Par6/aPKC complex) to regulate front-rear polarity.

PC-1 and Par3 Associate Functionally and Physically *in vivo* {#S7}
-------------------------------------------------------------

As the Par3/aPKC complex was reported to regulate CE in Drosophila and lower vertebrates^[@R23],[@R24],[@R20]^ we next investigated if PC-1 interaction with Par3/aPKC could be detected *in vivo* using our unique murine model of tagged endogenous PC-1^[@R10]^. First, we found that the expression levels and cleavage products of PC-1 in the developing kidney in the time-window when CE occurs (E13.5 to P1, [Fig. 5a,b](#F5){ref-type="fig"}) are regulated. Notably, the full-length uncleaved PC-1 levels are maximal in the kidney at E13.5 and progressively decrease during development up to birth, though it is visible in longer exposure times ([Fig. 5c](#F5){ref-type="fig"}), the cleaved CTF increases progressively and the P100^[@R25]^ only appears in the newborn kidneys ([Fig. 5c](#F5){ref-type="fig"}). Importantly, the expression pattern of Par3, and specifically the 180kDa isoform^[@R26]^, overlaps with that of full-length PC-1. Second, immunoprecipitation of endogenous HA-PC-1 resulted in co-precipitation of Par3 and aPKC in total embryos at E15.5 ([Fig. 5d](#F5){ref-type="fig"}), in the developing kidneys at E17.5 ([Fig. 5e](#F5){ref-type="fig"} and [Supplementary Figure S2](#SD1){ref-type="supplementary-material"}) and in P1 newborn kidneys ([Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}). Finally, we analysed the aPKC-complexes and found that immunoprecipitation of aPKC reveals that it preferentially associates with Par3 in *Pkd1^+/+^* E17.5 kidneys, while it preferentially associates with Par6 in E17.5 *Pkd1^ΔC/ΔC^* mutant kidneys ([Fig. 5f,g](#F5){ref-type="fig"}). These data are in line with the composition of the complexes observed in cells ([Fig. 4b,c](#F4){ref-type="fig"}). Since the *Pkd1^ΔC/ΔC^* mutants lack the intracellular C-tail of PC-1, our studies support the notion that this region is essential for PC-1 proper function during renal tubular morphogenesis.

Defective convergent extension in Par3-mutant kidneys {#S8}
-----------------------------------------------------

We next reasoned that if direct interaction between PC-1 and Par3 is essential to mediate correct CE and renal tubular narrowing, we would predict that mice mutant for *Par3* display a similar defect than *Pkd1* mutants. Homozygous deletion of *Par3* results in embryonic lethality before E12.5, preventing analysis of renal development^[@R27]^. Thus, we intercrossed a line harbouring a conditional allele for *Par3*^[@R27]^ with a line carrying a *Hoxb7:Cre* (confining Cre expression in the Ureteric Bud, UB)^[@R28]^. Anti-Par3 antibodies staining confirmed that the protein is lost in a high percentage of cells at E15.5 and at P1 ([Supplementary Fig. S4](#SD1){ref-type="supplementary-material"}). The resulting mice (Hoxb7Cre:Par^3flox/−^) displayed a defective number of cells per tubular cross-sections in DBA-positive tubules at E16.5 ([Fig. 6a,b](#F6){ref-type="fig"}). Importantly, the Par3 mutants displayed a defective mediolateral orientation of epithelial cells ([Fig. 6c](#F6){ref-type="fig"}). A defective number of cells per tubular cross-sections was also observed at P1 ([Fig. 6a,b](#F6){ref-type="fig"}), when a few cysts and tubular dilatations were also observed in 4 out of 10 Hoxb7Cre:Par3^flox/−^ mice ([Fig. 6d](#F6){ref-type="fig"}). Importantly, in E15.5 DBA-positive tubules the rates of cell division were not affected in the *Par3* mutants, while apoptosis was slightly increased ([Supplementary Figure S4](#SD1){ref-type="supplementary-material"}). Furthermore, analysis of markers of apico-basal polarity and tight junctions formation revealed no major defects at this level in the epithelia lacking Par3 ([Fig. 6e](#F6){ref-type="fig"} and [Supplementary Figure S4](#SD1){ref-type="supplementary-material"}), in line with previously published studies^[@R26]^. We conclude that indeed Par3 is essential for proper CE during renal development in the mouse and that this process is independent of Par3 function in apico-basal polarity, but possibly relies on PCP, as recently demonstrated^[@R5]^.

Discussion {#S9}
==========

In this study we have uncovered a critical role for PC-1 in the recently described CE process essential to achieve proper tubular elongation and morphogenesis. In wild-type developing kidneys, DBA-positive tubules are composed of an average of 13 cells at E13.5 and an average of 7 cells by E16.5. We have shown that in *Pkd1* mutant kidneys DBA-positive tubules fail to undergo this program of tubular narrowing. Previous studies have shown that the epithelium of the developing nephron divides in a non-oriented manner, but it undergoes mediolateral cellular orientation^[@R4]^. Since this is a hallmark of tissues undergoing a program of convergent extension (CE) to achieve elongation and narrowing^[@R29],[@R30]^ this prompted investigators to hypothesize and subsequently to demonstrate that the developing nephron is shaped through CE-like movements^[@R4],[@R3]^. Indeed, cellular intercalation appears to be the mechanism that best explains how epithelial tubules can narrow over time despite the absence of oriented cell division (which should in principle result in increased diameter). Here we have shown that the epithelium of DBA-positive tubules lacking functional PC-1 fails to orient mediolaterally suggesting that PC-1 plays an essential role in this process. Our study further uncovers a role for PC-1 in regulation of a program of cell polarity enabling cells to properly achieve cellular elongation and front-rear asymmetry during migration in wound healing assays. We have shown that PC-1 interacts with the aPKC/Par3 (180 kDa) complex and likely regulates it to achieve polarized cell migration.

It is interesting to note that PC-1 interacts with both Par3 and aPKC, but not with Par6. Furthermore, the biochemical composition of the aPKC-containing complexes appears to be altered in *Pkd1* mutant cells and kidneys. In wild-type cells, able to properly polarize during migration, aPKC preferentially binds to Par3. In contrast, in cells lacking functional PC-1 aPKC appears to preferentially bind to Par6. In addition, over-expression of Par6 is able to compete with Par3 for binding to aPKC, and in line with this, it is able to subtract aPKC from the PC-1/Par3/aPKC complex. This prompted us to hypothesize that Par6 and Par3 might actually compete for binding aPKC. Our data are in line with previous models proposed mostly based on studies in *Drosophila* demonstrating that Bazooka (Par3) and Par6 can associate into distinct complexes with different functional roles^[@R31]^. Furthermore, a recent study has demonstrated that a competitive binding between Crumbs and Par6 can modulate the exclusion of Par3 from the Par6/aPKC complex, providing further support for a fine-tuned regulation of the so called "Par6/Par3/aPKC complex" by competitive binding ^[@R31]^.

It is noteworthy that Par3 (180 kDa isoform) and PC-1 appear to follow a similar developmental regulation that parallels the timing of tubular morphogenesis described above. The two proteins are associated *in vivo* in total embryos and in the developing kidney. We hypothesized that this association might be essential for regulating mediolateral cell orientation and CE during renal tubular morphogenesis. The essential role of the Pars/aPKC complex in regulation of CE downstream of the planar cell polarity pathway has been demonstrated in *Drosophila Melanogaster*^[@R24],[@R20]^ while a single study has implicated their role in lower vertebrates^[@R19]^. Here we have demonstrated that inactivation of *Par3* in the ureteric bud of the developing kidney results in defective narrowing of the tubular diameter and defective mediolateral orientation of the epithelia composig these tubules. Thus, our data imply for the first time a role for Par3 in CE and tubular morphogenesis in a mammalian system.

While our studies provide important novel insight in the function of PC-1 and its role in renal development, one important question that remains unanswered is if and how defective CE might result in cyst formation. We show that only approximately 40% of the *Hoxb7-Cre:Par3^−/flox^* mice develop cysts. Thus, defective CE alone might not be sufficient to cause cyst formation and compensatory mechanisms might exist. Similarly, in a previous study, Nishio et al have shown that defective oriented cell division (OCD) does not initiate cyst formation in the newborn kidney, since mice mutant for *Pkhd1* display defective OCD, but not cyst formation^[@R8]^. It was proposed that a compensatory mechanism of intercalation might prevent cyst formation in these mice. Thus, one possibility is that neither defects in OCD nor in CE alone are sufficient to initiate cyst formation, but they both might contribute.

In sum, in this study we have described a novel role for PC-1 in regulation of a program of cell polarity, important to achieve proper tubular morphogenesis during renal development. Further studies will be required to assess if this biological function of PC-1 is important for preventing cyst formation and it is relevant for the disease.

Methods {#S10}
=======

Antibodies and Inhibitors {#S11}
-------------------------

Anti-αtubulin and anti-flag antibodies were obtained from Sigma (cat 77418-1EA, T5168, T6793, F1804 respectively). Anti phospho-PKCλ/ζ (Thr410/403) (cat 9378) from Cell Signaling. Dapi (cat sc-3598), anti-PKCζ (sc-216 / sc-216-G), anti-Par6 (cat sc-14405), anti-Polycystin-1 (cat sc-130554), anti-His (cat sc-8036) and anti-Gst (cat sc-495) from Santa Cruz. Anti-HA from Roche (rat monoclonal cat 13948000). Anti-Par3 from Millipore (cat 07-330, diluted at 1:300 for immunofluorescence, at 1:1000 for western blot). Anti-E-cadherin from Invitrogen (cat 131900). Anti-Giantin (cat PRB-114C) and anti-pericentrin (cat PRB-432C) from Covance. Anti-ezrin -- from Millipore (07-130, 1:100) ; anti-occludin from Invitrogen (71-1500, 1:500); anti-beta-catenin from Sigma (C7207, 1:500) ;anti-laminin from Sigma (l9393, - 1:500,); anti-CK from Sigma (C2562, 1:500). Rhodamine conjugated-DBA (*Dolichos Biflorus Agglutinine*) from Vector Laboratories (cat RL-1032). All primary antibodies were diluted according to the manifacturer's instructions unless otherwise stated. HRP-conjugated secondary antibodies (GE Healthcare) were diluted at a 1:7000, detection was made with an ECL system (Amersham)

Analysis of *Pkd1* mutant mice {#S12}
------------------------------

The *Pkd1*^ΔC^ mouse model has been previously generated and carries loxP sites flanking the last two exons of the *Pkd1* gene (exons 45 and 46)^[@R10]^. Timed pregnant mice were obtained by overnight crossing wild-type or *Pkd1*^ΔC\ /+^ mice in 100% Bl6/57, and checking for vaginal plugs the next morning. The presence of a vaginal plug was defined as gestational day E0.5 (embryonic day 0.5). All embryos were collected at the defined embryonic stages (between E13.5 and P1 as specified in the legends) and were 50%females and 50% males. Wild-type and mutant live (based on heart beating) littermate embryos were evaluated from a minimum of three independent litters. All animal care and experimental protocols on the *Pkd1* mutants were conducted upon approval of a specific protocol (IACUC-548) by the institutional care and use ethical committee (I.A.C.U.C.) at the San Raffaele Scientific Institute. For biochemical studies we collected and pooled kidneys at day E13.5, 15.5, E17.5 or P1, lysed them with 0.5% triton-lysis buffer; immunoprecipitation were performed as described below for *in-vitro* studies.

Evaluation of tubular diameter *in vivo* {#S13}
----------------------------------------

For the evaluation of the number of cells / tubular cross section, 12μm sections of E13.5, 15.5, 16.5 or P1 kidneys were stained with the marker Dolichos Biflorus Agglutinin (DBA) and the nuclear marker DAPI. Nuclei of circle-shaped kidney DBA-positive tubules were counted, excluding from analysis the oval-shaped tubules that have values of ovality at the ImageJ software \<0.995 (i.e. tubules that are not perpendicuarly cross-sectioned). We performed two independent experiments for E13.5, E15.5, E16.5 live (based on heart beating) littermate embryos, counting 100 wt and 100 mutant tubules for each experiment, as well as for P1 wt kidneys. Whenever the phenotype of the embryos was not overt the analysis were performed in a blinded manner. For the evaluation of circumference and diameter: for round-shaped tubules, a circumference was tracked going through the centre of all the nuclei of the tubular section; the measure of the circumference and of the related Feret's diameter was quantified by ImageJ software.

Evaluation of Cellular Orientation *in vivo* {#S14}
--------------------------------------------

For the evaluation of cell elongation and orientation, E15.5 embryos were fixed ON in ice-cold methanol, included in 5% low melting agarose, cut in 100-150μm section with a vibratome and stained with DBA, anti-E-cadherin, anti-PKCζ antibodies and DAPI. Z-stacks of renal tubules were captured every 1μm, using UltraView spinning disk confocal microscope (PerkinElmer) with Volocity software. For the evaluation of mediolateral orientation, ell shape was tracked using the authomated Magnetic Lasso tool (Photoshop), on E-cadherin staining in sections taken two frames below (basal to) PKC staining. Only cells in the image where E-cadherin staining outlined the entire cell were used for calculations (cells on the edges that had discontinuous E-cadherin staining were not measured). For all other cells the length (longest axis) to width (shortest axis) ratio were calculated. Only cells for which the ratio was greater than 1.2 were considered elongated. Those that have a lower ratio (between 1 and 1.2) are depicted in grey and were not considered elongated. For all the others the angle between the longest axis of the cell and the longitudinal axis of the tubule were calculated using imageJ software^[@R4]^.

Apoptosis and proliferation *in vivo* {#S15}
-------------------------------------

To monitor apoptosis, cryostat kidney sections of 12 μm were stained with terminal Transferase dUTP Nick End Labeling (TUNEL) was carried out using the DeadEnd™ Fluorometric TUNEL System Kit according to the manufacturer's protocol (Promega). Sections were co-stained for *Dolichos biflorus* agglutinin (DBA) used at the dilution 1/100 (Vector Laboratories). For proliferation, sections were permeabilized in TritonX-100 blocked with PBS-BSA (Bovine Serum Albumin) 3%-NGS (Normal Goat Serum) 10% at room temperature for 1h, incubated over night with the anti-body anti-Ki67 or anti Phh3 at 4°C, washed and incubated with secondary anti-bodies (Alexa Fluor conjugated secondary antibodies, from Invitrogen-Molecular Probes) and *Dolichos biflorus* agglutinin (DBA) used at the dilution 1/100. The ProLong Antifade kit (Invitrogen-Molecular Probes) was used for mounting the samples.

Wound-healing Assays {#S16}
--------------------

MDCK (Madin-Darby Canine Kidney, type II) and MEF (Mouse Embryonal fibroblasts) cells were grown on cover slips as high density monolayers, wounded using a 200μl pipette tip, and allowed to migrate for 3 hours (unless otherwise indicated).

For immunofluorscence studies, PFA or methanol-fixed cells were washed, permeabilized in PBS/0,5% Triton X-100, and blocked (PBS, 3% BSA). Primary antibody was applied (all antibodies were diluted 1:100 in blocking and incubated for 1 hour at 37°C) followed by washes and incubation with secondary antobodies (Alexa Fluor conjugated secondary antibodies, from Invitrogen-Molecular Probes). The ProLong Antifade kit (Invitrogen-Molecular Probes) was used for mounting the samples. ). Digital images of representative fields were captured using a Zeiss Axiophot fluorescence microscope or UltraView spinning disk confocal microscope (PerkinElmer) equipped with a Plan Apochromat 63X/1.4 oil-immersion objective and using the UltraView ERS acquisition software.

For time-lapse studies, cells on the wound edge were tracked using the public domain ImageJ program (developed at the National Institutes of Health and available at <http://rsb.info.nih.gov/ij/>). The rate of uni-directional movement was determined following a minimum of 10 different cells trajectories from 9 movies of three independent experiments (for a total of 102 cells) and measuring the angle formed by the cell trajectories and the perpendicular to the wound edge.

Transfection and cell sorting {#S17}
-----------------------------

MDCK cells were transiently transfected using Lipofectamine 2000 (Invitrogen). Details on the composition of the lysis buffers are in [supplementary informations](#SD1){ref-type="supplementary-material"}. For immunoprecipitation (IP) studies, cells were collected at 4 °C in 0.5% Triton-X100 lysis buffer and lysed for 30 min on ice. Nuclei were discarded after centrifugation at 13200rpm for 10 min. For HA-tagged PC-1 immunoprecipitation equal amounts of proteins were incubated overnight at 4°C with Anti-HA Affinity Matrix (Cat 11815016001, Roche); after washes, immunoprecipitates were run on NuPAGE Novex 3-8% TrisAcetate Gel (cat EA0375BOX, Invitrogen). For PKCζ IP studies equal amount of proteins were incubated in rocking with the primary anti-PKCζ antibody overrnight at 4°C, then G-sepharose beads (Cat 17-0618-01, GE Healthcare) were added and incubated 2 hours at RT. Immunoprecipitations were followed by immunoblotting with the indicated primary antibodies (see above). For cell sorting experiments parental MDCKtypeII cells were transiently transfected using Lipofectamine 2000 (Invitrogen) according to the Manufacturer's directions by using 12 μg total DNA. For cell sorting, transfections were performed using a construct expressing Green Fluorescent Protein (pEGFP-N1, Clontech) as a marker for cell sorting in combination with PC-1 different constructs (see [Fig. 2d](#F2){ref-type="fig"}). The following day cells were analyzed by FACS Vantage DIVA sorter (Becton Dickinson). GFP-positive cells were sorted, re-plated in 60 mm dishes containing coverslips and after 36h cells were analyzed by western blotting or challenged by wound-healing followed by IF to nuclei and Golgi/MTOC as described. Full western blots are shown in [Supplementary Fig. S5](#SD1){ref-type="supplementary-material"}.

Immunoprecipitation studies and GST pull-down assays {#S18}
----------------------------------------------------

For immunoblotting, immunoprecipitation and GST-pull down assay, lysis buffer was composed by 150 mM NaCl, 20 mM NaP, 10% glycerol (pH 7.2), supplemented with phosphatase inhibitors (200 mM glycerol phosphate, 200 mM Na orthovanadate, 500 mM Na fluoride), protease inhibitor cocktail (Complete, Roche), and Triton X-100 as indicated.

For GST pull-down assays, the indicated GST-fused PDZ domains of Par3, and HIS-fused C-terminus of PC-1 (aa4132-4303) were expressed in E.coli strain BL21. Bacteria were lysed by sonication in 0.1% Triton X-100 lysis buffer and cleaned by centrifugation. GST-fused proteins supernatants were incubated ON at 4°C with glutathione beads. Beads were centrifuged, washed, and incubated with HIS-fused PC-1 supernatants 3 h at 4°C (1:60 in volume of this supernatant was used in immunoblotting as input). After centrifuging and washing the beads, proteins were solubilized in Laemmli buffer and analyzed by immunoblotting. Full western blots are shown in [Supplementary Fig. S5](#SD1){ref-type="supplementary-material"}.

PAR3 silencing {#S19}
--------------

Control-non targeting siRNA pool (cat\# D-001206-13-20) and three siRNA targeting Par3 (Par3\#1: AGACAGACUGGUAGCAGUAUUUU; Par3\#2: GUGAAAUUGAGGUCACGCUUUU; Par3 \#3: GUGAAAUUGAGGUCACGCCUU) as well as scramble controls were obtained from Thermo Scientific-Dharmacon. To transiently silence Par3 we used Lipofectamine™ (Invitrogrn) transfection, following the manifacturer's directions.

Par3 mutants generation and analysis {#S20}
------------------------------------

Hoxb7Cre mice^[@R27]^ were bred to mice carrying a mutant allele of Pard3 (Ref.[@R26]). Hoxb7Cre;Par3^+/−^ males were crossed to females that were homozygous for an allele of Pard3 in which the third coding exon was flanked by lox-p sites (*Par3^flox/flox^*). Noon of the day of vaginal plugging was considered embryonic day 0.5. Litters (half females and half males) were collected at various timepoints for mutant analysis and genotyped by PCR. For cre recombinase, the following primers were used: Hoxdb7Cre forward 5′- GGT CAC GTG GTC AGA AGA GG-3′ ; Hoxdb7Cre reverse 5′- CTC ATC ACT CGT TGC ATC GA-3′. Presence of Hoxb7Cre results in a 400 bp product. For Par3, the following primers were used: −423iF 5′- AGG CTA GCC TGG GTG ATT TGA GAC C -3′; −159iR 5′- TTC CCT GAG GCC TGA CAC TCC AGT C -3′; +382iF 5′- GTC TGT GGG GGT TTT GGG AGA GAG G -3′ resulting in products of 371 bp (lox), 292bp (null) and 265 bp (wildtype) when resolved on a 3% agarose gel. Mutant embryos (*b7Cre;Par3^−/flox^*) were compared to littermates either with no Cre (*Par3^−/flox^*) or no null allele (*b7cre;Par3^+/flox^*). All animals for these studies were housed, maintained and used according to protocols approved by the Institutional Animal Care and Use Committees at the University of Texas Southwestern Medical Center (animal protocol number 1048-06-01-1)

Statistical Analysis {#S21}
--------------------

Student's T-test or one way analysis of variance (ANOVA) was applied to establish differences between means for *in vitro* studies. Multiple comparisons were carried out using the Bonferroni parameter. Non parametric Mann-Whitney test was used for the distribution of the angles of migration ([Fig. 2b](#F2){ref-type="fig"} and [Supplementary Fig. S3](#SD1){ref-type="supplementary-material"}) and for the distribution of cell orientation in the developing tubules ([Fig. 1e](#F1){ref-type="fig"} and [Fig. 6c](#F6){ref-type="fig"}).
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![Defective tubular narrowing and cellular morphology in *Pkd1* mutants\
(**a**) Histogram of the percentage (y axis) of DBA-positive tubules with a given number of cells (x axis) per tubule cross-section at E13.5, E15.5 and E16.5 in wild-type (top, grey bars) or *Pkd1^ΔC/ΔC^* (bottom, orange bars) kidneys. The squares and bars on top show the average and the distribution (maximum and minimum numbers), respectively. (**b**) Graph extrapolated from the data in **a.** histograms and bars represent the average and standard error of the means (SEM). At E13.5 n=183 (WT), n=182 (KO), at E15.5 and E16.5. n=200 for both the genotypes, where n indicates the number of tubules counted. Statistical analysis was carried out by ANOVA followed by the Bonferroni parameter. n.s. non-significant ; \*\*p\<0.01; \*\*\*p\<0.001. (**c**) Representative sections of DBA-positive (red) developing tubules at E16.5 of *Pkd1^+/+^* or *Pkd1^ΔC/ΔC^* kidneys. Each cell is labelled with an asterisk and the number of cells per cross-section indicated in the lumen. Bar: 20μm. (**d**) Confocal Images (left panels) and cell outlines (right panels) of frontal sections of E15.5 wild-type (*Pkd1^+/+^*) or *Pkd1* mutant **(***Pkd1^ΔC/ΔC^*) kidneys stained with antibody to E-cadherin in DBA-positive sections. Images in the left panels represent sections two frames basal to the aPKC staining, as previously described^[@R4]^. Mediolaterally elongated cells are labelled in white, proximal-distally in black, non-elongated cells in grey. Bar: 10μm. (**e**) Quantification of the angle of cellular elongation relative to the proximal-distal axis of the tubule for *Pkd1^+/+^* (left) and *Pkd1^ΔC/ΔC^* (right). The percentage of cells within each 10° increment is shown. White bars represent cells elongated mediolaterally within a 40°-90° angle. N=530 cells for wild-type and N=575 for mutants in a minimum of six kidneys from three litters. p\<0.0001. Statistical analysis was performed using the Mann-Whitney test.](emss-54838-f0001){#F1}

![PC-1 Controls Polarized Migration\
(**a**) Tracking of cells of *Pkd1*+/+ and −/− MEFs in 12hrs wound-healing time-lapse experiments. Each colored line is a cell. (**b**) Scheme and quantification of the experiments in **a.** The angle of deviation α of each trajectory from a theoretical linear migration (equal to angle 0°) was calculated. N=102 cells from 9 movies in 3 independent experiments per cell line. Statistical analysis was performed using the Mann-Whitney test. p\<0.0001. (**c**) **Left.** *Pkd1+/+* or *−/−* MEFs subject to wound-healing followed by immunofluorescence with an anti-α-tubulin (green), anti-pericentrin (red) and DAPI (blue). Bar: 20μm**. Right**. Quantification of front-rear polarity on three independent MDCK^PKD1Zeo^ clones (36, 68 and G3) and two independent MDCK^Zeo^ (F2 and F6), on *Pkd1*^+/+^ or *Pkd1^−/−^* MEFs or *Pkd1^flox/flox^* MEFs treated or not with a Cre-recombinase. The red line shows a theoretical random distribution (33%). Statistical Analysis was performed using the Student's T-test (for MEFs, left) or ANOVA (for PKD clones, right) followed by the Bonferroni parameter. \*\*p\<0.01; \*\*\*p\<0.001. Data are means ± SD and are representative of a minimum of three independent experiments performed in triplicate, in which at least 300 cells were counted. (**d**) Diagram of PC-1 different isoforms and/or mutant constructs. (**e**) Immunoblot of PC-1 in fibroblasts, or in MDCK*^PKD1Zeo^* (36) and MDCK*^Zeo^* (F2) using an anti-LRR antibody (7e12), detects both the full-length (FL-PC1, approx 520kDa) and the cleaved, N-terminal fragment (NTF, approx 400kDa). No signal is observed in *Pkd1−/−* cells. (**f**) Immunoblot of endogenous tagged PC-1 using an anti-HA detects two bands corresponding to the full-length uncleaved PC-1 (FL-PC1, approx 520kDa) and the C-terminal Fragment (CTF, approx 150kDa). Treatment with a Cre-recombinase causes disappearance of FL-PC-1-HA detection. (**g**) MDCKtypeII were transiently transfected with GFP alone or along with full-length PC-1 (FL-PC1), the R4227X or the CTF HA-tagged mutants. After sorting, cells were treated as in **c**. Data are means ± SD; Statistical analysis was performed using ANOVA followed by Bonferroni parameter. \*\*\*p\<0.001, n.s. non-significant. (**h**) Immunoblot of transfected cells in **g** with anti-HA antibody.](emss-54838-f0002){#F2}

![PC-1 Interacts with the Par3/aPKC Complex\
(**a**) MEFs isolated from a mouse model carrying HA-tagged endogenous PC-1^[@R10]^ or from littermate embryos (WT) were subject to immunoprecipitation with anti-HA antibodies. Western blot using anti-HA antibodies revealed the presence of both full-length (arrow, approx520kDa) as well as cleaved CTF (asterisk, approx 150kDa) isoforms of endogenous, tagged PC-1. Immunoblot analysis of the same immunoprecipitations using anti-PKCζ and anti-phosphoThr410-PKCζ revealed that PKCζ (78kDa) interacts with PC-1 in its active form. ; analysis using anti-Par3 antibodies reveals that PC-1 co-precipitated also with Par3 180kDa (**§**) and Par3 100kDa (°); analysis using anti-Par6 (43kDa) antibodies revealed that this molecule is not immunoprecipitated. Blot is representative of multiple independent experiments. (**b**) Transient transfection of a kinase-dead mutant (KD-PKCζ) or a wild type form (WT-PKCζ) in MDCK^PKD1Zeo^ cells (68 and 36). Data are means ± SD. Statistical analysis was performed using ANOVA followed by Bonferroni parameter. \*\*p\<0.01. n.s. non-significant. (**c**) Schematic representation of the aPKC, Par6 and three different isoforms of Par3; arrows indicate the described interacting domains. (**d**) Hek293T cells were transiently transfected with HA-tagged full-length PC-1 (PC-1-HA) along with the 180kDa and 100kDa forms of Par3, followed by immunoprecipitation with anti-HA antibodies. The blot is representative of two independent experiments. (**e**) GST-tagged versions of each of the three PDZ domains of Par3 were immobilized on G-sepharose beads, and subsequently incubated with HIS-PC-1-CT. Immunoblot with anti-GST revealed that equal amounts of GST-PDZ domains of Par3 were immobilized on the beads. Anti-HIS showed that PC-1-CT interacts with the first two PDZ domains, but not with the third.](emss-54838-f0003){#F3}

![PC-1 can influence the ratio of Par3 vs Par6 bound to aPKC\
(**a**) MEF cells were subject to wound, fixed and stained for anti-tubulin (green) and anti-Par3 (red). Bars: 20μm (**b**) Immunoprecipitation from *Pkd1^+/+^* or *Pkd1^−/−^* MEFs using an anti-PKCζ antibody followed by immunoblotting with an anti-Par3 (180-150-100kDa) or anti-Par6 (43kDa) antibody, in *Pkd1^+/+^* and *Pkd1^−/−^* MEFs. CT, cell lysate from *Pkd1^+/+^* MEFs was incubated in the absence of primary anti-PKC antibody. The blot is representative of seven independent experiments. (**c**) Quantification of the intensity of bands from seven independent experiments carried out as in **b**. Data are means ± SEM. Statistical analysis was performed using ANOVA followed by Bonferroni parameter. \*\*p\<0.01. (**d**) GFP positive cells, transfected with GFP, Par6 (/GFP), or Par3 (180kDa, YFP tagged, N=50-120), as well as transfected with three Par3 siRNA (\#1-3, N=600), were analysed for the capability to polarize in wound-healing assays as in [Fig. 2c](#F2){ref-type="fig"}. Data are means ± SD, and representative of three independent experiments performed in triplicate. Statistical analysis was performed using ANOVA followed by Bonferroni parameter. \* p\<0.05, n.s. non-statistically significant. (**e**) Pkd1^+/+^ or Pkd1^HA/HA^ MEFs were transfected with increasing amounts of Par6A expressing constructs, followed by immunoprecipitation with anti-HA beads followed by western blot analysis with anti-aPKC (78kDa), anti-Par3 (180kDa) anti Par6 (43kDa) or anti-HA antibodies (full-length PC-1 approx520kDa and CTF approx150kDa). (**f**) The experiment was performed as in **e**, except that the *Pkd1^HA/HA^* MEFs were transfected with Par6 or Par6^K19A^ construct (43kDa), mutated in the aPKC binding site^[@R22]^.](emss-54838-f0004){#F4}

![PC-1 Interacts with and Regulates Par3/aPKC in the Developing Kidneys\
(**a**) Images of DBA-positive tubules at the stages indicated show narrowing of the tubules. Bar: 20μm. (**b**) Histogram quantifying the process illustrated in **a**; graphs are average ± SEM of the number of cells per tubule cross-section. (**c**) Western blot analysis on lysates derived from pools of E13.5, E15.5, E17.5 and P1 developing kidneys from *Pkd1^HA/HA^* mice, using anti-HA (top panel), anti Par3 (middle panel) and anti-phosphorylated (T410) or total levels of aPKC antibodies (bottom panel). Representative western blot of three independent experiments. Arrow, full-length PC-1 (approx 520kDa); \*, CTF cleavage product of PC-1 (approx 150kDa); \*\*P100 cleavage product of PC-1 (approx 100kDa); **§**, 180 kDa Par; **\#**, 150 kDa Par3; **°**, 100 kDa Par3. (**d**) E15.5 total embryo lysates from *Pkd1^HA/HA^* (HA) or *Pkd1^+/+^* (WT) mice were used to immunoprecipitate PC-1 using anti-HA antibodies, followed by immunoblotting with anti-HA (top), anti-Par3 (middle) or anti PKCζ antibodies (bottom). Arrow, full-length PC-1 (approx 520kDa); \*, CTF cleavage product of PC-1 (approx150kDa) ; **§**, 180 kDa Par; **\#**, 150 kDa Par3; **°**, 100kDa Par3. (**e**) PC-1 was immunoprecpitated from kidneys of *Pkd1^HA/HA^* or *Pkd1^+/+^* at E17.5 using anti-HA antibodies, followed by immunoblotting with anti-HA, anti- Par3 and anti-aPKC antibodies. Arrow, full-length PC-1 (approx 520kDa); \*, CTF cleavage product of PC-1 (approx150kDa); **§**, 180kDa Par. (**f**) Immunoprecipitation analysis from E16.5 *Pkd1^+/+^* or *Pkd1^ΔC/ΔC^* kidneys using an anti-PKCζ antibody followed by immunoblotting with an anti-Par3 or anti-Par6 (43kDa) antibody. CT, cell lysate from *Pkd1^+/+^* embryonic kidneys was incubated in the absence of primary anti-PKC antibody. The blot is representative of three independent experiments. (**g**) Quantification as means ± SEM of the intensity of bands from three independent experiments performed as in **f**,. Statistical analysis was performed using ANOVA followed by Bonferroni parameter. \*\*p\<0.01.](emss-54838-f0005){#F5}

![Defective convergent extension in Par3 mutants\
(**a**) Histograms showing the distribution of the number of cells per cross section of tubules as in **1a** of wild-type (grey bars, N=100) and *Hoxb7Cre:Par3^flox/−^* mutant (orange bars, N=100) developing kidneys at E16.5 or P1; N indicates the number of tubules counted. CTRL: controls are either *Hoxb7Cre:Par3^flox/+^* (at P1) or *Par3^flox/−^* (at E16.5). (**b**) Graph extrapolated from the data in **a**; histograms and bars represent the average and standard error of the means (SEM). Statistical analysis was performed by analysis of variance (ANOVA) followed by the Bonferroni parameter \*\*\*\*p\<0.0001. (**c**) Quantification of the angle of cellular elongation relative to the proximal-distal axis of the E15.5 tubule for WT or *Hoxb7Cre:Par3^flox/−^* (right), as in [Figure 1e](#F1){ref-type="fig"}. 483 cells for wild-type and mutants in a minimum of six kidneys from three litters were counted. p\<0.0001. Statistical analysis was performed using the Mann-Whitney test. (**d**) Hematoxylin and eosin staining of *Hoxb7Cre:Par^flox/+^* and *Hoxb7Cre:Par3^flox/−^* mutant kidneys at P1 show tubular dilatation and small cysts in the Par3 mutants. Scale bar: 100μm. (**e**) Sections of Control (*Par3^flox/−^*, left panel) and mutant (*Hoxb7Cre;Par3^flox/−^*, right panel) P1 kidneys stained with antibodies to atypical Protein Kinase C (aPKC) (red), beta-catenin (green) and the collecting duct maker DBA (purple) in the top panel. In the bottom panel, sections were stained with Laminin (red), E-cadherin (green) and the collecting duct marker cytokeratin (blue). No differences were observed in protein localization/polarity between control and mutant collecting ducts. Bar: 20μm.](emss-54838-f0006){#F6}
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